-
I-Mab and MorphoSys License Drugs to HIBio in Global Oncology Deal
•
China-based I-Mab (NASDAQ: IMAB) detailed a licensing and equity investment deal between its German partner MorphoSys AG (FSE: MOR; Nasdaq: MOR) and U.S. biotech Human Immunology Biosciences, Inc. (HIBio). Under the agreement, MorphoSys granted HIBio global rights to develop and commercialize two drugs: the CD38 antibody felzartamab and the C5aR1…
-
Adicon Holdings and Guardant Health Partner on Genomic Profiling in China
•
China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, to bring Guardant’s comprehensive genomic profiling (CGP) tests to biopharmaceutical firms conducting clinical trials in China. The deal grants Adicon access to Guardant’s liquid biopsy technology, including the Guardant360,…
-
BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development
•
China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with compatriot company InnoRNA, a specialist in lipid-nanoparticle (LNP)-based delivery technology and mRNA drug discovery. The collaboration aims to leverage InnoRNA’s innovative platform for developing mRNA-based therapeutics. Agreement TermsUnder the deal, InnoRNA will receive an upfront…
-
PackGene and SineuGene Partner on ALS Gene Therapy Research
•
China-based PackGene has entered into another partnership with compatriot firm SineuGene. This time, the focus is on plasmid pharmaceutical research, adeno-associated virus (AAV) pharmaceutical research, AAV batch release testing, analytical methodology development, stability research, and more. The collaboration aims to support SineuGene’s lead pipeline candidate SG001, a genetic therapy under…
-
China Establishes Leadership Group to Combat Drug-Related Crimes
•
China’s State Council executive body released a notification regarding the establishment of a leadership group aimed at cracking down on crimes that could impact drug safety and endanger the public. The group will consist of several State Council deputies and leaders from key government agencies, including the National Medical Products…
-
Phil Rivers Tech Raises RMB 100 Million for Computational Medicine Push
•
Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100 million (USD 14.9 million) in a Series A financing round. The funding was led by Insight Capital and Tenaya Capital, with participation from Highthink Med. The proceeds will be used for the upgrade of its…
-
Gan & Lee Pharmaceuticals Doses First Patient in GZR101 Phase I Study
•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed in a China-based Phase I clinical study for its drug candidate GZR101. The first-in-human study aims to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of the GZR101 injection and its component GZR33. Drug Details and…
-
Fosun Pharma’s FS-1502 Gets NMPA Approval for Gastric Cancer Study
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study for its HER2 monoclonal antibody (mAb) injection FS-1502 in HER2-expressing advanced gastric cancer patients. The study will evaluate the…
-
GeneScience’s Somatropin Wins NMPA Approval for Prader-Willi Syndrome
•
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its somatropin to treat Prader-Willi Syndrome (PWS). This latest approval marks the tenth indication for the company’s somatropin and represents the first approval for a home-grown growth hormone…
-
Inmagene and HutchMed Dose First Patient in IMG-007 Global Phase I Study
•
China-based Inmagene Biopharmaceuticals and HutchMed (NASDAQ: HCM, HKG: 0013) announced the completion of first patient dosing in a global Phase I clinical study for their IMG-007 in Australia. The drug, an antagonistic monoclonal antibody (mAb) targeting OX40, was discovered by HutchMed. Inmagene owns exclusive global option rights to the drug…
-
ClinChoice Raises USD 150M in Funding Led by Legend Capital for Expansion
•
Sino-US full-service Contract Research Organization (CRO) ClinChoice has reportedly raised USD 150 million in a financing round led by Legend Capital. Other investors included Taikang Life Insurance, Sherpa Healthcare Partners, Lilly Asia Ventures, Apricot Capital, and SIP Oriza Seed Fund. The proceeds will be used for business expansion, new business…
-
InnoCare Pharma’s BCL2 Inhibitor ICP-248 Accepted for NMPA Review
•
China’s Beijing InnoCare Pharma (HKG: 9969) announced that an investigational new drug (IND) filing for its in-house developed BCL2 inhibitor ICP-248 has been accepted for review by the National Medical Products Administration (NMPA). ICP-248 is a Category 1 innovative drug with independently held intellectual property rights. Drug ProfileInnoCare plans to…
-
Shenzhen TargetRx Raises Hundreds of Millions in Series B Financing for Drug Development
•
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, reportedly raised “hundreds of millions” of renminbi in a Series B financing round, with investors undisclosed. The proceeds will go towards pivotal clinical studies for TGRX-678 and TGRX-326, development of other drug candidates, and product pipeline expansion. Company and ProductsFounded…
-
Ascletis Pharma Files IND Application for ASC10 with US FDA
•
China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has filed an Investigational New Drug (IND) application for ASC10, an oral RNA-dependent RNA polymerase (RdRp) inhibitor being developed to treat COVID-19, with the US FDA following a pre-IND consultation. Drug ProfileASC10 is an orally bioavailable, double prodrug of the antiviral…
-
MabPharm’s CMAB017 Receives NMPA Approval for Clinical Study in Solid Tumors
•
Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its Category 1 innovative drug candidate CMAB017 in advanced solid tumors. The trial will include patients with colorectal cancer, head and…
-
Zhejiang Medicine’s NovoCodex Subsidiary Receives RMB 402M Investment
•
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that investors will inject a financial dose of RMB 402 million (USD 60 million) into its subsidiary NovoCodex Biopharmaceuticals Ltd, amounting to a combined 12.94% stake in the firm. Milestones AchievedSince the closure of its Series A financing round, NovoCodex has achieved…
-
Medicilon Biomedical Plans RMB 2.16B Private Placement for R&D Expansion
•
China-based Shanghai Medicilon Biomedical Co., Ltd has announced plans to raise RMB 2.16 billion (USD 322 million) through a private placement. The proceeds will be used for the Shanghai biomedicine research and development (R&D) innovation industry base program, drug discovery and pharmaceutical research and filing platform laboratory expansion program, and…
-
Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval from the National Medical Products Administration (NMPA) for its generic version of Pfizer’s Ibrance (palbociclib). The drug can now be used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced…
-
Alibaba Health’s 2022 Financial Report Shows Revenue Growth, Net Loss
•
China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the year ended March 31, 2022), with revenues reaching RMB 20.57 billion (USD 3 billion), up 32.6% year-on-year (YOY). The growth was driven by the pharmaceutical self-operation business and medical and digital service business. However, the…
-
Wuxi Biologics Set to Be Removed from US Restricted Trade List
•
Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US Department of Commerce restricted trade list, a development first reported in February this year. This news has significantly boosted the firm’s valuation, wiping away HKD 77 billion (USD 9.9 billion) in losses. Chinese authorities permitted…
